BSX Boston Scientific Corp
- Stocks
- Healthcare
- NYSE: BSX
Price (delayed)
$102.96
Market cap
$152.56B
P/E Ratio
60.56
Dividend/share
N/A
EPS
$1.7
Enterprise value
$163.61B
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology,
Highlights
Boston Scientific's net income has increased by 37% YoY and by 23% QoQ
The EPS has increased by 37% YoY and by 23% from the previous quarter
BSX's quick ratio is down by 32% year-on-year and by 4.4% since the previous quarter
Boston Scientific's debt has increased by 10% YoY and by 2.5% QoQ
Key stats
What are the main financial stats of BSX
Market
Valuations
Earnings
Shares outstanding
1.48B
Market cap
$152.56B
Enterprise value
$163.61B
Price to earnings (P/E)
60.56
Price to book (P/B)
6.79
Price to sales (P/S)
8.24
EV/EBIT
49.02
EV/EBITDA
35.16
EV/Sales
8.85
Revenue
$18.49B
Gross profit
$12.63B
Operating income
$3.15B
Net income
$2.51B
EBIT
$3.34B
EBITDA
$4.65B
Free cash flow
$3.5B
Per share
Balance sheet
Liquidity
EPS
$1.7
EPS diluted
$1.68
Free cash flow per share
$2.36
Book value per share
$15.15
Revenue per share
$12.5
TBVPS
$10.96
Total assets
$41.56B
Total liabilities
$18.91B
Debt
$11.59B
Equity
$22.42B
Working capital
$1.93B
Debt to equity
0.52
Current ratio
1.37
Quick ratio
0.65
Net debt/EBITDA
2.38
Margins
Efficiency
Dividend
EBITDA margin
25.2%
Gross margin
68.3%
Net margin
13.5%
Operating margin
17%
Return on assets
6.3%
Return on equity
11.5%
Return on invested capital
16.1%
Return on capital employed
9.2%
Return on sales
18%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BSX stock price
How has the Boston Scientific stock price performed over time
Intraday
0.01%
1 week
-1.87%
1 month
-0.84%
1 year
39.55%
YTD
15.27%
QTD
-4.14%
Financial performance
How have Boston Scientific's revenue and profit performed over time
Revenue
$18.49B
Gross profit
$12.63B
Operating income
$3.15B
Net income
$2.51B
Gross margin
68.3%
Net margin
13.5%
Boston Scientific's net income has increased by 37% YoY and by 23% QoQ
Boston Scientific's operating income has increased by 28% YoY and by 10% from the previous quarter
The revenue has increased by 21% YoY and by 5% from the previous quarter
Boston Scientific's gross profit has increased by 20% YoY and by 4.8% QoQ
Price vs fundamentals
How does BSX's price correlate with its fundamentals
Growth
What is Boston Scientific's growth rate over time
Valuation
What is Boston Scientific stock price valuation
P/E
60.56
P/B
6.79
P/S
8.24
EV/EBIT
49.02
EV/EBITDA
35.16
EV/Sales
8.85
The EPS has increased by 37% YoY and by 23% from the previous quarter
The P/E is 26% below the 5-year quarterly average of 82.1 and 12% below the last 4 quarters average of 69.0
The stock's price to book (P/B) is 54% more than its 5-year quarterly average of 4.4 and 4.5% more than its last 4 quarters average of 6.5
The equity has grown by 10% YoY
BSX's P/S is 37% above its 5-year quarterly average of 6.0
The revenue has increased by 21% YoY and by 5% from the previous quarter
Efficiency
How efficient is Boston Scientific business performance
BSX's ROIC is up by 25% YoY and by 16% from the previous quarter
The return on equity has increased by 24% year-on-year and by 20% since the previous quarter
The return on assets has grown by 24% year-on-year and by 19% since the previous quarter
The ROS has increased by 13% YoY and by 13% from the previous quarter
Dividends
What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BSX.
Financial health
How did Boston Scientific financials performed over time
Boston Scientific's total assets is 120% more than its total liabilities
BSX's quick ratio is down by 32% year-on-year and by 4.4% since the previous quarter
BSX's total liabilities is up by 15% year-on-year and by 7% since the previous quarter
Boston Scientific's debt is 48% lower than its equity
Boston Scientific's debt has increased by 10% YoY and by 2.5% QoQ
The equity has grown by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.